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Summary  The  human  cytomegalovirus  (CMV)  is  a  major  cause  of  congenital  infec-
tions.  A  case—control  descriptive  study  was  conducted  in  Kirkuk,  Iraq  to  determine
the  seroprevalence  of  CMV  in  women  with  bad  obstetric  history  (BOH)  compared
to  women  with  a  normal  previous  pregnancy.  The  CMV  IgG  and  IgM  seroprevalence
was  higher  in  women  with  BOH.  The  CMV  IgG  seroprevalence  was  signiﬁcantly  inﬂu-
enced  by  pregnancy,  age,  residence  and  level  of  education.  In  addition,  the  current
CMV  infection  was  signiﬁcantly  associated  with  pregnancy,  age,  residence  and  edu-
cation.  Large  families  (crowding  index  >3)  exhibited  higher  seroprevalence  for  CMV
IgM  (8.3%)  and  IgG  (98.3%),  but  odd  ratio  (OR)  showed  no  signiﬁcant  association
between  family  size  and  seropositivity.  The  CMV  IgG  seropositivity  was  higher  in
working  women  (100%)  compared  to  housewives  (95.4%).  However,  the  CMV  IgM  (cur-
rent  infection)  was  6.8%  in  housewives  and  was  not  detected  in  any  working  women
(0%).  The  OR  exhibited  no  signiﬁcant  association  between  occupation  and  both  IgM
and  IgG  levels.
©  2014  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.∗ Corresponding author at: Department of Microbiology, Tikrit
niversity College of Medicine, Tikrit, Iraq.
el.: +964 7705861455.
E-mail addresses: galsamarrai@yahoo.com,
khzen@yahoo.com (Z.K.M. Aljumaili).
I
T
c
i
f
a
876-0341/$ — see front matter © 2014 King Saud Bin Abdulaziz University for Health
ttp://dx.doi.org/10.1016/j.jiph.2013.08.006ntroduction
he  human  cytomegalovirus  (HCMV)  is  a major
ause of  congenital  infections.  This  virus’s  clin-
cal manifestations  range  from  asymptomatic
orms (90%  of  cases)  to  severe  fetal  damage
nd, in  rare  cases,  death  due  to  abortion  [1].
 Sciences. Published by Elsevier Ltd. All rights reserved.
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Cytomegalovirus  (CMV)  infection  during  pregnancy
is far  more  complex  than  other  infections  because
the virus  can  frequently  be  reactivated  during
the child-bearing  years  and  can  be  transmit-
ted to  the  fetus  despite  maternal  immunity
[2].
There  are  many  confounding  studies  describ-
ing the  association  between  CMV  infection  and
pregnancy  loss,  which  show  that  HCMV  can  result
in abortion  or  stillbirth  [3,4]. HCMV  acts  as  an
immune  modulator  by  using  an  array  of  immune
evasion strategies  to  avoid  elimination  from  the
host, and  its  viral  proteins  are  involved  in  the  regu-
lation of  cellular  gene  expression  and  the  induction
of pro-inﬂammatory  cytokines  [5]  or  an  autoim-
mune response  [6]. In  another  study  in  Waset
province, Iraq  [7], women  with  a  history  of  abor-
tion showed  60.2%  IgM  seropositivity;  however,  this
not signiﬁcantly  different  from  the  control.  A  high
percentage  of  repeated  abortions  (two  and  three
or more)  occurred  in  women  seropositive  for  CMV
IgM.
In Mosul,  Iraq  [8], 12%  of  women  of  child-bearing
age were  seropositive  for  cytomegalovirus  (CMV);
therefore,  the  majority  cases  of  congenital  CMV
infection  are  likely  a  result  of  maternal  reinfection.
In Baghdad  city,  Iraq,  IgM  antibodies  signiﬁcantly
correlate with  a  history  of  abortion  [9].  In  another
study of  women  with  habitual  abortions  in  the  Thi
Qar Governorate,  Iraq,  60  of  60  women  (100%)  had
antibodies  against  CMV,  with  9  women  (15%)  with
IgM antibodies,  21  women  (35%)  with  IgG  antibodies
and 30  women  (50%)  with  both  IgM  and  IgG  antibod-
ies [10].
Cytomegalovirus  is  frequently  a  causative  agent
of prenatal  and  perinatal  infection  and  may  lead  to
pregnancy complications  [11]. The  seropositivity  of
CMV varies  widely  worldwide  [12].  A  review  of  40
global  studies  on  CMV  seroepidemiology  indicated
a range  of  seropositivity,  from  30.4%  in  Ireland
[13]  to  98.9%  in  Turkey  [14]  in  pregnant  and/or
child-bearing age  women.  In  addition,  the  sero-
prevalence  rate  ranged  from  14.2%  in  Iran  [15]  to
91.05% in  India  [16]  in  women  with  a  bad  obstetric
history.
In Arab  countries,  we  reviewed  21  studies,  which
indicated a  seroprevalence  rate  ranging  from  77.8%
in Babylon,  Iraq  [17]  to  88%  in  Jordan  [18]  in
pregnant women.  The  seroprevalence  ranged  from
4.8% in  Baghdad,  Iraq  [19]  to  95%  in  Jordan  [18]  in
women with  a  bad  obstetric  history.
The objective  of  the  present  study  is  to
determine the  seroprevalence  of  CMV  in  women
with a  bad  obstetric  history  and  the  sociode-
mographic characteristics  that  may  inﬂuence
seropositivity.
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atients and methods
etting
irkuk  General  Hospital,  Primary  Health  Care  Cen-
ers in  Kirkuk  Governorate.
tudy design
his  study  is  a descriptive  case—control  study.
tudy area
his  descriptive  case—control  study  was  conducted
t the  antenatal  clinic  of  the  Kirkuk  General  Hos-
ital and  Primary  Health  Care  Centre  in  Tessean.
omen (pregnant  or  not  pregnant)  with  a  bad
bstetric  history  were  recruited  from  the  outpa-
ient Gynaecology  Clinic  Kirkuk  General  Hospital  or
he outpatient  Clinic  at  Tessean  PHC.
tudy population
he  study  population  comprises  women  of  child-
earing age.  The  study  population  was  recruited
rom the  Primary  Healthcare  Centers  located  in
rban and  rural  areas  in  Kirkuk  Governorates.  In
ddition,  one  study  population  group  was  recruited
rom pregnant  women  in  labor  to  obtain  the  group
f pregnant  women  with  risky  outcomes.
Group  1:  Pregnant  women  aged  15—48  years  with
normal  pregnancy.
Group 2:  Non-pregnant  women  aged  15—48  years
with normal  pregnancy.
Group  3:  Pregnant  women  with  BOH  depending
on their  previous  pregnancy  and/or  delivery  out-
come, which  includes  pregnancy  loss,  intrauter-
ine deaths,  preterm  deliveries  and  intrauterine
growth retardation.  Their  ages  ranged  from  15  to
48 years.
Group  4:  Non-pregnant  women  with  BOH
depending on  their  previous  pregnancy  and/or
delivery outcome,  which  includes  pregnancy
loss, intrauterine  deaths,  preterm  deliveries
and intrauterine  growth  retardation.  Their  ages
ranged  from  15  to  48  years.
The demographic  information  of  these  groups  is
hown in  Table  1.  The  target  number  recruited  for
ach group  was  150  women.  However,  the  total
umber  of  women  included  in  the  study  was  538,
f which  293  (54.5%)  had  BOH  and  245  (45.5%)
ad a normal  pregnancy  history.  In  the  BOH  group,
44 (49.1%)  women  were  pregnant,  whereas  in  the
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Table  1  Study  population.
Group  Number  Mean  age  ±  SD  in  years
Women  with  bad
obstetric  history
Pregnant  144  27.38  ±  7.5
Non  pregnant  149  28.56  ±  6.7
Total  293  27.97  ±  7.1
Women  with
normal  pregnancy
Pregnant  117  26.00  ±  6.2
Non  pregnant 128  30.16  ±  10.9
Total 245  28.16  ±  9.2
Grand  total 538  28.06  ±  8.1
P  value ANOVA >0.05
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dormal  pregnancy  group,  117  women  (47.7%)  were
regnant.
ollection of data
he  investigators  visited  the  outpatient  department
aily, selected  the  study  subjects  and  screened
he patients  using  a  predesigned,  pretested  sched-
le based  on  the  inclusion  and  exclusion  criteria
o identify  and  recruit  the  study  subjects.  The
ext  available  age-matched  multiparous  antenatal
oman  without  BOH  was  included  in  the  control
roup subjects.
Clinical  examination  and  laboratory  investiga-
ions were  performed  for  the  study  subjects  to
xclude  other  causes  of  abortion  or  fetal  death,
uch as  hypertension,  diabetes  mellitus,  syphilis,
h (rhesus)  incompatibility,  physical  causes  of
bortion,  and  consanguinity.  Subjects  with  known
auses  of  fetal  wastage  were  excluded  from  the
tudy. All  subjects  were  interviewed  to  ascertain
ge and  medical  and  obstetric  information.
ample collection
or  serological  analysis,  5—10  mL  of  venous  blood
as  collected  from  each  study  subject  in  a  ster-
le container  with  strict  aseptic  precautions.  The
erum  was  separated  and  stored  in  numbered
liquots at  −20 ◦C  until  it  was  assayed.  All  serum
amples collected  from  the  study  and  control
roups were  tested  for  CMV  IgM  and  IgG  antibodies
sing commercially  available  ELISA  kits.  The  results
ere read  with  a  microwell  reader  and  compared  to
he controls.  The  optical  density  was  read  at  450  nm
n an  ELISA  reader.thical approval
he  ethical  committee  of  the  institute  approved
he research  protocol.  The  purpose  and  procedures
c
s
a
tf  the  study  were  explained  to  all  study  subjects,
nd informed  consent  was  obtained.  The  study
esign  was  approved  by  the  ethical  committee  of
UCOM registered  in  the  USA  [U.S.  Department  of
ealth and  Human  Services  (HHS)  &  Registration
f an  Institutional  Review  Board  (IRB)].  IORG  #:
ORG0006885.
Institution:  Tikrit  University  College  of  Medicine
TUCOM] OMB  No.  0990-0279.
ethods
LISA  was  used  to  determine  the  IgM  and  IgG  levels
or HSV-2  and  the  test  was  performed  according  to
he manufacturer’s  instructions.  The  kit  was  pur-
hased from  BioCheck,  Inc.,  323  Vintage  Park  Dr.,
oster City,  CA  94404.
ata analysis
he  collected  data  were  compiled  in  a Microsoft
xcel spreadsheet.  The  proportions  and  odds  ratios
ere computed  for  the  appropriate  analyses.
o determine  whether  there  was  an  association
etween the  categorical  data,  a Chi  square  test
as used  with  the  SPSS  software  (Version  16.0,
icenced to  TEAM  EQX).  If the  sample  size  in  the
OH group  did  not  reach  the  targeted  number,
 power  analysis  will  be  performed  to  determine
he accuracy  of  the  ﬁndings.  The  study  data  are
resented  as  the  frequency  ± SD  and  the  95%  con-
dence  interval.  Bivariate  regression  line  analysis
as performed  to  calculate  the  odds  ratio  to  deter-
ine  an  association  between  two  variables.  The
eterminants  for  CMV  infection  were  determined  by
alculation  of the  odds  ratio  using  a  logistic  regres-
ion line  analysis.  Confounding  factors,  such  as  age
nd socio-economic  status  were  standardized  when
he serological  determinants  were  calculated.
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Table  2  Cytomegalovirus  seroprevalence  in  women  with  bad  obstetric  history.
Group  [number]  Number  positive  [%]
IgM  IgG
Bad  obstetric  history Pregnant  [144] 12  [8.3] 140  [97.2]
Non-pregnant  [149]  9  [6]  143  [96]
X2 0.579  0.347
P  value  >0.05  >0.05
Total  [293]  21  [7.2]  283  [96.6]
Normal  pregnancy Pregnant  [117]  13  [11.1]  104  [88.9]
Non-pregnant  [128]  0  [0]  128  [100]
X2 15.02  15.02
P  value 0.000 0.000
Total  [245]  13  [5.3]  232  [94.7]
Grand  total  [538]  34  [6.3]  515  [95.7]
X2 BOH  versus  normal  pregnancy  0.7  1.169
>0.05  >0.05
Table  4  Frequency  of  cytomegalovirus  in  regard  to
age.
Age  group  in
years
Number  HSV-2,  number  [%]
IgM  IgG
15—19  74  1  [1.4]  74  [100]
20—29  238  24  [10.1] 220  [92.4]
30—39  172  7  [4.1]  167  [97.1]
40—48  54  2  [3.7]  54  [100]
Chi  square  10.9  12.8
4
l
h
C
wP  value  BOH  versus  normal  pregnancy  
Bold values indicated a signiﬁcance difference.
Results
The  overall  CMV  seroprevalence  in  our  study  popu-
lation was  95.7%  and  was  higher  in  women  with  BOH
(96.6%) compared  to  women  with  normal  pregnancy
(94.7%) outcomes  (X2 = 1.169,  P  >  0.05).  Further-
more, the  current  CMV  infection  was  higher  in
women  with  BOH  (7.2%)  than  in  women  with  nor-
mal pregnancy  (5.3%)  outcomes  (X2 = 0.7,  P  >  0.05)
(Table  1).  However,  there  was  a  signiﬁcant  dif-
ference (X2 =  6.206,  P =  0.013)  in the  CMV  IgG
seroprevalence  between  pregnant  (93.5%)  and
non-pregnant  (97.8%)  women.  In  addition,  the  cur-
rent infection,  as  demonstrated  by  IgM  positivity,
was signiﬁcantly  higher  (X2 = 9.093,  P  =  0.003)  in
pregnant  women  (9.6%)  compared  to  non-pregnant
(3.2%) women  (Table  2).
Age signiﬁcant  seroprevalence  variation  was
demonstrated  for  both  the  IgG  (X2 =  12.8,  P  = 0.005)
and IgM  (X2 =  10.9,  P  =  0.012)  antibodies.  CMV  IgG
seropositivity  was  100%  in  women  aged  <  20  years,
and  then  declined  in  women  20—29  years  of age,
but subsequently  increased  to  100%  in  women  aged
Table  3  Cytomegalovirus  seroprevalence  in
pregnant  compared  to  non-pregnant  women.
Group  [number]  Number  positive  [%]
IgM  IgG
Pregnant  [261] 25  [9.6]  244  [93.5]
Non-pregnant  [277]  9  [3.2]  271  [97.8]
X2 9.093  6.206
P  value  0.003  0.013
Bold values indicated a signiﬁcance difference.
a
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(P  value 0.012 0.005
Bold values indicated a signiﬁcance difference.
0—48  years.  The  CMV  IgM  seroprevalence  was
owest in  women  <20  years  of  age  (1.4%),  and
ighest (10.1%)  in  women  aged  20-29  years.  The
MV IgM  seroprevalence  then  declined  to  3.7%  in
omen aged  40—48  years  (Table  3).  OR  conﬁrmed
 signiﬁcant  association  between  the  age  and  CMV
gM (OR  =  2.1003,  P  =  0.04)  and  CMV  IgG  (2.7061,
 =  0.04)  seroprevalence  (Table  4).  OR  conﬁrmed
he association  between  age  >30  years  and  CMV  IgG
OR =  2.7061,  P  =  0.04)  seropositivity,  whereas  CMV
gM seropositivity  was  associated  with  age  <30  years
OR =  2.1003,  P  =  0.04)  (Table  5).
Table  5  Odd  ratio  of  cytomegalovirus  in  regards  to
age  of  women  lower  than  30  years.
Variable  Odd  ratio  [95%
conﬁdence  interval]
P value
CMV  IgM  2.1003  [0.9608—4.5911]  0.04
CMV  IgG  2.7061  [0.9895—7.4008]  0.04
Bold values indicated a signiﬁcance difference.
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Table  6  Frequency  of  HSV  2  IgG  and  IgM  in  regard  to  sociodemographic  characteristics.
Variable  [Number]  Number  positive  [%]
IgM  IgG
Residence
Rural [140] 0  [0] 140  [100]
Urban  [398]  34  [8.5]  375  [94.2]
X2 12.76  8.45
P  value  0.000  0.004
Occupation
House  wife  [497]  34  [6.8]  474  [95.4]
Working  [41]  0  [0]  41  [100]
X2 2.99  1.98
P  value  >0.05  >0.05
Education
Uneducated  [34]  5  [14.7]  34  [100]
Primary  [331]  14  [4.2]  321  [97]
Secondary  [105]  1  [1]  105  [100]
College  and  above  [68]  14  [20.6]  55  [81]
X2 49.95  62.77
P  value  0.000  0.000
Crowding  index
≤3  [478]  29  [6.1]  456  [95.4]
3.1—8  [60] 5  [8.3] 59  [98.3]
X2 0.24  1.12
P  value >0.05  >0.05
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hBold values indicated a signiﬁcance difference.
All  women  living  in  rural  areas  were  seropositive
or CMV  IgG,  whereas  in  urban  areas,  the  seropos-
tivity was  94.2%  and  was  signiﬁcantly  difference
X2 =  8.45,  P  =  0.004).  However,  the  current  infec-
ion was  signiﬁcantly  (X2 = 12.76,  P = 0.000)  higher
n women  from  urban  (8.5%)  areas  and  was  not
etected in  women  from  rural  (0%)  areas  (Table  6).
R conﬁrmed  the  association  between  residence
nd CMV  seroprevalence  for  both  IgM  (OR  = 26.5967,
(
o
Table  7  Association  of  HSV  2  seropositivity  with  sociodem
Variable  
Occupation  [housewife  versus
ofﬁcial]
IgM  
IgG  
Crowding  index  [<3  versus  >3]
IgM  
IgG  
Education
Uneducated
I
Primary  
Secondary  
College  and
above
Uneducated
versus
educated
I
Residence  [rural  versus  urban]
IgM  
IgG  
Bold values indicated a signiﬁcance difference. = 0.02)  and  IgG  (OR  =  17.5859,  P  =  0.04)  antibodies
Table  7).
CMV IgG  seropositivity  was  higher  (X2 =  1.98,
 > 0.05)  in  working  women  (100%)  compared
o housewives  (95.4%).  However,  the  CMV  IgM
eroprevalence  (current  infection)  was  6.8%  in
ousewives  and  was  not  detected  in  working  women
0%). OR  showed  no  signiﬁcant  association  between
ccupation  and  both  IgM  (OR  =  0.1619,  P >  0.05)
ographic  characteristics  using  bivariate  analysis.
Odd  ratio  [95%  conﬁdence  interval]  P  value
0.1619  [0.9997—2.6882]  NS
0.2433  [0.0145—4.0777]  NS
0.7105  [0.2641—1.9112]  NS
0.3513  [0.0465—2.6544]  NS
gG
16.7800  [0.9665—291.471]  0.05
7.5870  [3.1700—18.1580]  <0.0001
51.3240  [2.9950—87.9660]  0.006
16.7838  [0.9665—291.471]  <0.05
gM  2.8240  [1.0179—7.835]  0.04
26.5967  [1.6195—436.7827]  0.02
17.5859  [1.0610—291.4844]  0.04
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and  IgG  seroprevalence  (OR  =  0.2433,  P  >  0.05)
(Tables  6  and  7).
The  education  level  signiﬁcantly  inﬂuenced
the CMV  seroprevalence  for  both  IgM  (X2 =  49.95,
P = 0.000)  and  IgG  (X2 =  62.77,  P =  0.000)  in  our
study population.  OR  conﬁrmed  this  association  for
IgM (OR  = 2.824,  P =  0.04)  and  IgG  (OR  = 7.58—16.78,
P = 0.05  to  <0.0001)  (Tables  6  and  7).  Large  (crowd-
ing index  >3)  families  had  higher  seroprevalence  for
CMV IgM  (8.3%)  and  IgG  (98.3%),  but  OR  showed  a
signiﬁcant  association  between  the  family  size  and
seropositivity  (Tables  6 and  7).
Discussion
The  present  study  shows  a  high  overall  seropreva-
lence of  CMV  IgG  (95.7%),  with  no  signiﬁcant
differences  between  the  rate  in  women  with  BOH
and those  with  normal  pregnancy.  Therefore,  the
susceptibility  rate  in  our  study  population  was  4.3%,
which was  higher  than  that  reported  for  Turkey
[14,20—23],  Nigeria  [24,25]  and  Brazil  [26].  How-
ever, our  study  susceptibility  was  lower  than  that
reported  for  Nepal  [27],  India  [28], Switzerland
[29],  Croatia  [30],  Malaysia  [31], Iran  [15,32,33],
Poland [34],  Ireland  [13],  Russia  [35],  Germany
[36],  Azerbaijan  [37],  Bangladesh  [38],  and  Brazil
[39].  Compared  to  Arab  countries,  the  study  sus-
ceptibility  rate  was  lower  than  that  reported  for
Egypt [40],  Sudan  [41], Saudi  Arabia  [42], Syria
[43],  Jordan  [18], Baghdad,  Waset,  Mosul,  Al-Anbar,
Al-Hila,  Thi  Qar,  Kirkuk,  Diwaniya,  and  Babylon
[7,8,17,18,44—50].
Both  the  present  study  and  global  reports  show
a high  seroprevalence  of  CMV  IgG  antibodies;
however,  preconceptional  immunity  against  CMV
provides  incomplete  protection  against  intrauter-
ine transmission,  and  adverse  outcomes  can  occur
in infected  children  born  to  women  who  were
seropositive prior  to  pregnancy  [51—55].
Transplacental  transmission  of  CMV  in  women
with preexisting  seroimmunity  may  occur  secondary
to virus  reactivation  [56]  or  to  infection  with  a
different  CMV  strain  (reinfection)  [57]  during  preg-
nancy.
Previous  immunization  with  CMV  is  not  abso-
lutely protective  against  either  reinfection  or
vertical  transmission  of  infection  from  mother
to fetus  [23]. In  a  recent  study,  approximately
one third  of  the  study  seroimmune  women  had
CMV reinfection  during  the  follow-up  visit  [57].  A
recent review  of  the  literature  indicated  that  the
incidence  of  congenital  CMV  infection  increases
with increasing  maternal  CMV  seroprevalence  [56].
The positive  correlation  between  higher  maternal
s
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eroprevalence  and  high  birth  prevalence  may
eem paradoxical  because  this  suggests  that  a
ewer number  of  pregnant  women  are  at  risk  for
rimary infection.  However,  in  a population  with
igh seroprevalence,  the  number  of  pregnancies  at
isk for  reactivation  is  also  increased.  In addition,
he high  seroprevalence  may  be  due  to  a  higher
revalence of  risky  behaviors  in  the  population.  In
 population  with  high  seroprevalence,  a pregnant
oman has  a  higher  likelihood  of  exposure  to
MV-infected people.  Therefore,  in  a  high  risk
opulation,  seropositive  women  have  a  higher  risk
f reactivation  and  seronegative  women  have  a
igher risk  of  primary  infection  [58].  Preventive
easures should  be  taken  to  decrease  perinatal
ortality and  morbidity  related  to  CMV  infection
nd to  ensure  that  women  are  not  infected  with
MV during  pregnancy.  Pregnant  women  should  be
onsulted and  encouraged  to  implement  these  pre-
entive measures.  Routine  nationwide  screenings
or CMV  should  be  considered,  although  serious
ost effectiveness  issues  must  be  evaluated  before
he implementation  of  such  screenings.
In Kirkuk,  the  CMV  seroprevalence  is  as  high
s 95.7%.  Routine  CMV  screening  in  such  a
opulation is  unnecessary,  but  there  are  excep-
ions. Pregnant  women  who  had  contact  with  a
atient with  a proven  acute  CMV  infection,  as
ell as  patients  with  upper  respiratory  system
nfection-like symptoms,  hepatomegaly,  elevated
iver enzymes,  lymphadenopathy  and  immunocom-
romised statuses  should  all  receive  screening  [23].
herefore, a routine  screening  test  is  usually  justi-
ed only  for  conditions  with  an  expected  high  rate
f infection,  conditions  that  have  a proven  mode  of
revention and  conditions  for  which  the  screening
ethod is  safe  and  inexpensive.  Currently,  routine
creening  for  CMV  is not  recommended  because
f the  high  prevalence  of  seropositivity.  Because
here is  no  consistently  effective  treatment  for  con-
enital CMV  infection,  testing  is  clinically  useless
nd expensive.  However,  Nigro  et  al.  [59]  recently
eported promising  results  for  passive  immunization
gainst congenital  CMV  infection.
In the  current  study,  there  was  no  signiﬁcant
ifference in  the  CMV  seroprevalence  between
regnant (97.2%)  and  non-pregnant  (96%)  women
ith  bad  obstetric  history.  However,  there  was
 signiﬁcant  difference  between  the  pregnant
88.9%) and  non-pregnant  (100%)  women  with  a
revious normal  pregnancy  (X2 = 15.02,  P  =  0.000).
urthermore,  the  CMV  IgG  seroprevalence  was
2igniﬁcantly  (X =  6.206,  P =  0.013)  higher  in  non-
regnant (97.8%)  compared  to  pregnant  (93.5%)
omen,  and  OR  conﬁrmed  the  association  between
ubella  IgG  seropositivity  and  pregnancy.
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CMV  IgG  seroprevalence  in  our  study  population
anged from  92.4%  to  100%  across  age  groups  and
howed  no  signiﬁcant  trends  with  age.  However,
here was  a  signiﬁcant  (X2 =  12.8,  P  = 0.005)  dif-
erence  in  seroprevalence  among  the  age  groups.
n addition,  the  women  aged  30  years  and  above
ad the  highest  prevalence  of  CMV  IgG  (97.7%,
21/226) compared  to  women  in  aged  <30  years
94.2%, 294/321).  This  difference  was  signiﬁcant
y OR  calculation  (OR  =  2.7061,  P =  0.04).  This  could
e because  as  women  age,  their  interactions  and
ncounters  with  risk  factors  increase  [60].  Our  ﬁnd-
ng was  consistent  with  that  reported  for  other
eographical areas  [23,41,60—62]. The  seropreva-
ence of  CMV  in  women  between  the  ages  of 15
o 19  years  was  high  (100%).  This  high  seropreva-
ence may  be  attributed  to  the  wide  practice
f breastfeeding  during  infancy  [63].  Breastfeed-
ng is  a  signiﬁcant  source  of  CMV  transmission
o children  and  plays  an  important  role  in  the
pidemiology of  CMV  infection  because  the  virus
s reactivated  during  lactation  in  nearly  every
eropositive mother  [64]. In  addition,  close  contact
nd crowdedness  in  primary  and  secondary  schools
ay contribute  to  this  increase  in  CMV  seropreva-
ence [65].  The  antibody  prevalence  was  reduced
92.4%) in  20—29-year-old  age  group.  This  ﬁnding
s not  consistent  with  that  reported  for  the  USA,  in
hich the  seroprevalence  increased  steadily  with
ge [66].  However,  this  result  was  consistent  with
hat reported  for  Portugal  [62].  Studies  with  simi-
ar age  groups  conducted  in  other  countries,  such  as
he USA,  Japan,  France,  England,  Poland,  and  Rus-
ia, report  seroprevalences  ranging  between  51.5%
nd 78%  [35,67—72].
The seroprevalence  of  women  with  CMV  IgG
radually increased  in  the  two  oldest  age  groups,
ith values  of  97.1%  and  100%,  suggesting  that  sex-
al transmission  was  an  important  route  of  viral
ransmission [73]. Another  recognized  source  of
dult CMV  infections  are  children.  CMV  infected
hildren shed  virus  in  their  saliva  and  urine  for
ears, providing  an  opportunity  for  continued
pread to  other  children  and  susceptible  adults,
uch as  close  relatives  and  teachers  [74,75].
It should  be  noted  that  in  our  study,  6.5%  of  the
regnant women  were  susceptible  to  CMV  and  9.6%
f the  pregnant  women  had  a  current  infection  that
ed us  to  conclude  that  there  is  considerable  risk
or congenital  infection  caused  by  maternal  primary
MV infection,  which  leads  to  fetal  infection  in
pproximately  40%  of  cases  (6%  congenital  infection
n our  cohort)  [76]. In  this  risk  group,  we  must  use
pproaches  to  prevent  congenital  CMV  infections,
hich include  the  improved  hygiene  of  seronega-
ive women  and  the  administration  of  hyperimmune
d
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lobulin  to  pregnant  women  with  primary  infection
r pregnant  women  with  previous  infections  who
ave CMV  antibody  titers  or  low  IgG  avidity  [77].
Child-to-mother transmission  of  CMV  during
regnancy in  seronegative  women  may  be  con-
rolled  or prevented  by  simple  hygiene,  such  as
requent  hand  washing,  wearing  gloves  for  speciﬁc
hildcare  tasks  and  avoiding  intimate  contact  with
heir child,  including  sharing  utensils,  food  or  tow-
ls, and  kissing  on  or  near  the  mouth  [78—80].
Despite advances  in  the  diagnosis  of
aternal—fetal  CMV  infection  and  approaches
o prevent  congenital  CMV,  an  effective  pre-
atal therapy  is  unavailable.  A  prospective,
on-randomized  study  of  pregnant  women  who
cquired  CMV  infection  during  pregnancy  and  who
eceived passive  immunization  with  CMV  HIG,
howed that  this  therapy  was  associated  with
 signiﬁcantly  reduced  risk  of  congenital  CMV
isease and  infection  and  had  no  adverse  effects
77,81,82].  Recent  case  reports  support  the  safe
dministration  of  oral  ganciclovir  to  mothers  of
MV-infected  fetuses,  with  no  teratogenic  side
ffects when  administered  during  the  early  stages
f pregnancy  [77,83,84].  The  efﬁcacy  of  ganciclovir
emains  to  be  deﬁned  in  controlled  trials.  Other
tudies regarding  the  treatment  of intrauterine
MV infection  using  maternal  oral  administration  of
alaciclovir showed  that  it  signiﬁcantly  decreased
he viral  load  in  fetal  blood  and  could  potentially
educe the  morbidity  of  prolonged  intrauterine
nfection [85].  The  absence  of  adverse  effects  or
eratogenicity  with  valaciclovir  is  compatible  with
ts clinical  use,  but  a well-designed,  randomized
ontrolled trial  is  necessary.  Currently,  there  is  no
pproved vaccine  for  CMV,  but  two  vaccines  are  in
hase II  studies.  One  vaccine  is  a  recombinant  vac-
ine containing  the  major  envelope  glycoprotein  B
f the  virus  with  the  adjuvant  MF59  (gB/MF59)  that
nduces high  levels  of  neutralizing  antibodies  and
s safe  and  immunogenic  in  adults  and  infants,  and
lso prevents  maternal  CMV  infection  [86,87]. The
ther vaccine  is  the  live  attenuated  CMV  Towne
train that  stimulates  neutralizing  antibodies
omparable to  those  induced  by  the  wild  type  virus
nd protects  renal  transplant  patients  from  severe
MV following  transplantation  [81,88].
The primary  intervention  for  the  prevention  of
MV infection  should  be  aimed  at women  who  wish
o become  pregnant,  women  who  care  for  chil-
ren and  immunocompromised  individuals.  These
ndividuals  to  whom  CMV  exposure  is  the  most
etrimental are  the  target  groups  for  possible
dministration of  a future  vaccine  [62].
In this  study,  rural  residents  had  the  highest
MV IgG  prevalence  of  100%,  whereas  for  urban
t
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residents,  the  CMV  IgG  seroprevalence  was  94.2%
(X2 =  8.45,  P  =  0.004).  The  association  between  CMV
IgG seroprevalence  and  residence  was  conﬁrmed
by OR  calculation  (OR  =  17.5859,  P  = 0.04),  which
is consistent  with  observation  that  low  socio-
economic status  is  a  strong  risk  factor  for  CMV
infection [89]. Our  ﬁnding  was  consistent  with  that
reported  for  other  geographical  areas  [60,90].
In relation  to  educational  status,  the  CMV
IgG seroprevalence  was  higher  in  uneducated
(100%), primary  (97%)  and  secondary  (100%)  edu-
cated women,  whereas  it  was  lower  (81%)  in
women with  college  level  and  higher  education
(X2 =  62.77,  P  =  0.000).  OR  conﬁrmed  the  asso-
ciation between  CMV  IgG  seroprevalence  and
uneducated women  (OR  =  16.78,  P  <  0.05),  primary
educated  (OR  =  7.587,  P  < 0.0001),  secondary  edu-
cated (OR  =  51.324,  P = 0.006)  and  college  level  and
higher educated  (OR  =  16.7838,  P =  0.05)  women.
This ﬁnding  is  consistent  with  that  reported  for
other countries  [41,60]. Illiteracy  and  low  educa-
tion levels  were  previously  observed  as  risk  factors
for increased  susceptibility  to  CMV  infection,
perhaps through  direct  contact  with  contagious
secretions from  their  own  children  and  poor  hygiene
practiced  by  these  women  [89,91—93].
Likewise,  low  socioeconomic  status  is a  strong
risk factor  for  CMV  infection  [89].  However,  in  Iraq,
it is  difﬁcult  to  investigate  the  socio-economic  sta-
tus of  these  pregnant  women  because  the  culture  is
based on  an  attitude  of  generous  hospitality  toward
guests  and  family  members  who  usually  lives  in
extended  families.
There was  a  higher  prevalence  of  CMV  IgG  among
working women  compared  to  housewives,  but  this
difference  was  not  signiﬁcant.  Using  bivariate  anal-
yses, OR  showed  no  signiﬁcant  association  between
occupation  and  CMV  IgG  seroprevalence.  This  ﬁnd-
ing is  consistent  with  that  reported  by  others  [60].
By contrast,  a  previous  study  indicated  that  CMV  IgG
seropositivity  occurred  more  often  in  housewives
compared to  women  with  other  occupations  [38].
The present  study  shows  a  higher  CMV  IgG  sero-
prevalence in  large  families  (crowding  index  >3)
(98.3%)  than  in  small  families  (95.4%),  but  the  dif-
ference was  not  signiﬁcant.  In  addition,  OR  showed
no association  between  the  crowding  index  and
CMV-IgG  seropositivity,  which  was  consistent  with
other reports  [92].  Housing  crowdedness  and  fam-
ily size  are  imperfect  measures  of  the  transmission
dynamics that  actually  determine  an  individual’s
risk of  exposure  [93]. No  signiﬁcant  association  was
found between  the  prevalence  of  congenital  CMV
and a  mean  household  size  of  more  than  3.0  per-
sons. Previous  studies  suggest  a  positive  correlation
of congenital  CMV  with  a  household  size  of  more
a
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han  three  persons  and  low  socioeconomic  status
75,58,94,95].
CMV  IgM  seroprevalence  in  the  women  included
n this  study  was  6.3%  and  varied  signiﬁcantly
etween pregnant  (9.6%)  and  non-pregnant  (3.2%)
omen (X2 =  9.093,  P =  0.003).  Although  the  CMV
gM seroprevalence  was  higher  in  women  with  bad
bstetric  history  (7.2%)  compared  to  women  with
 normal  pregnancy  (5.3%),  the  difference  was  not
igniﬁcant.  However,  the  current  infection  of  9.6%
nd 6.5%  in  seronegative  and  pregnant  women,
espectively, represents  a  high  rate  of  risk  for  fetal
nfection.
Globally  reported  CMV  IgM  seropositivity  ranges
rom  0%  for  Turkey  [22]  to  13%  for  Poland  [34]  in
regnant  women  and  from  0%  for  India  [28]  to  8.42%
or India  [6]. In  Arab  countries,  the  range  of  CMV
gM seropositivity  was  from  2.3%  for  Jordan  [18]  to
7.2% for  Babylon,  Iraq  [17]  in  pregnant  women,
hereas in  women  with  BOH,  it  ranged  from  1.4%
or Jordan  [18]  to  60.2%  for  Waset,  Iraq  [7].  There-
ore, the  ﬁndings  of  the  present  study  for  women
ith normal  pregnancy  and  with  BOH  are  within  the
eported ranges  worldwide  and  for  Arab  countries.
owever, the  current  CMV  infection  rate  in  our
tudy  was  similar  to  that  reported  for  Waset  [7],
abylon [17],  Diwaniya  [50], Mosul  [8],  Baghdad
44,49,96],  and  Al-Hila  [45]. In  addition,  the  rate
as similar  to  that  reported  for  Thi  Qar  [47]  and
irkuk [48].
The CMV  IgM  seroprevalence  varies  signiﬁcantly
y age  (X2 =  10.9,  P  =  0.012),  with  the  highest  rate  of
urrent infection  (8%)  in  young  women  (<30  years)
ompared  to  older  women  (>30  years)  (4%,  X2 =  3.6,
 =  0.05).  This  ﬁnding  is  consistent  with  previous
tudies, which  showed  that  elderly  persons  appear
o be  protected  against  CMV  infection  because  of
he accumulation  of  CD28  effector  cytotoxic  T  lym-
hocytes  [60]. This  is  a characteristic  feature  of  all
ge groups  but  is  most  pronounced  in  elderly  per-
ons [97]. However,  there  is  considerable  debate
egarding  maternal  age  and  CMV  infection.  Many
nvestigators  have  observed  that  elderly  women
ere at  a  higher  risk  of  CMV  infection  [60,89],
hereas  others  have  reported  the  reverse  [98]  or
bsence  of  variation  by  age  [66]. All  the  above  ﬁnd-
ngs are  consistent  with  the  understanding  that  CMV
gM can  be  produced  over  the  course  of  a  lifetime
fter primary  infection  or  as  the  result  of  rein-
ection or  reactivation  [99,100]. This  suggests  that
ome older  cohorts  may  be  as  likely  to  have  recur-
ent episodes  of  CMV  as  younger  people  are  to  have primary  infection  [66].
Risk factors  based  on  residence  (OR  =  26.5967,
 =  0.02),  education  (OR  =  8.5842,  P  =  <0.0001),  age
OR =  2.1003,  P =  0.04)  and  pregnancy  (OR  =  3.1544,
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 =  0.004)  emerged  for  CMV  IgM  seroprevalence
n contrast  to  the  crowding  index  (OR  =  0.7105,
 =  >0.05)  and  occupation  (OR  =  0.1619,  P >  0.05).
owever,  Staras  et  al.  [67]  reported  that  age  was
ot a  risk  for  CMV  IgM  seropositivity,  but  conﬁrmed
hat age  was  a risk  for  CMV  IgG  seropositivity.  The
ack of  identiﬁable  risk  factors  for  CMV  IgM  may  be
ecause  of  the  relatively  small  number  of  observa-
ions, and  because  over  80%  of  the  IgM  reactivity  in
he tested  sample  was  with  high  avidity  and  there-
ore presumably  from  a  non-primary  CMV  infection,
hich may  be  less  associated  with  identiﬁable  risk
han a  primary  infection  [66].  In  addition,  a  portion
f the  IgM  positive  sera  may  have  been  false  posi-
ive determinations,  which  is known  to  occur  with
MV IgM  testing  [101].
The current  CMV  infection  was  more  predomi-
ant in  urban  women  (8.5%),  and  this  ﬁnding  was
ot consistent  with  previously  reported  studies
60,96,102]. In  addition,  there  were  no  signiﬁ-
ant differences  for  the  current  CMV  infection  with
egard to  occupation;  however,  the  current  infec-
ion was  signiﬁcantly  different  between  poorly  and
ighly educated  women  (X2 =  5.53,  P  <  0.0001).  Kolo
t al.  [60]  reported  a  high  prevalence  of  CMV  IgM  in
regnant  women  with  primary  education,  which  is
onsistent with  reports  from  the  United  States  and
estern Europe.
In conclusion,  maternal  CMV  infection  in  Kirkuk,
raq population  still  represent  a  health  problem
hat should  be  considered  by  local  healthcare
roviders.
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